FGFR4 Human shRNA Plasmid Kit (Locus ID 2264)

Snippet: Fibroblast growth factor receptor (FGFR)1 and FGFR4 have been associated with tumorigenesis in a variety of tumour types. As a therapeutic approach, their inhibition has been attempted in different types of malignancies, including lung cancer, and was initially focused on FGFR1-amplified tumours, though with limited success. …We provide in vitro and in vivo evidence showing that expression of the adhesion molecule N-cadherin is key for the oncogenic role of FGFR1/4 in non-small cell lung cancer. According to this, assessment of the expression of genes in different lung cancer patient cohorts showed that FGFR1 or FGFR4 expression alone showed no prognostic potential, and that only co-expression of FGFR1 and/or FGFR4 with N-cadherin inferred a poorer outcome. Treatment of high-FGFR1 and/or FGFR4-expressing lung cancer cell lines and patient-derived xenografts with selective FGFR inhibitors showed high efficacy, but only in models with high FGFR1/4 and N-cadherin expression. Our data show that the determination of the expression of FGFR1 or FGFR4 alone is not sufficient to predict anti-FGFR therapy efficacy;complementary determination of N-cadherin expression may further optimise patient selection for this therapeutic strategy. …All rights reserved.;- FGFR1 (RC202080) and FGFR4 (RG204230) cDNA clones were obtained from Origene in the pCMV6 plasmid (PS100001) For FGFR1 and FGFR4 silencing, shRNAs in the p-RS plasmid were purchased from Origene (TF320354 and TR320356, respectively);complementary determination of N-cadherin expression may further optimise patient selection for this therapeutic strategy. …

Snippet: with pRS vector control (TR20003, Ori- gene Technologies, Rockville, MD) and FGFR4-specific HuSH 29mer shRNA constructs (TR320356, Origene) and selected ... Hence Huh7 pro- vides a good culture model to study the effects of KLB perturbation in a more aggressive setting.